Viveve Medical Inc. initiated an underwritten public offering of its common shares.
The company also plans to grant the underwriters an option to buy up to an additional 15% of common shares.
Viveve plans to use the net proceeds to fund the commercialization of its products, clinical research and development, working capital and general corporate purposes.
Cowen is acting as the sole book-running manager of the offering.
